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Abstract 
 
CD82 is a tetraspanin involved in tumour metastasis suppression.  It is downregulated in 
several cancers including breast, liver and prostate cancer.  Although interactions with gangliosides 
and cholesterol have been demonstrated, no ligand has yet been identified to directly target CD82. 
CD82 interaction with gangliosides has been explored by immunoprecipitation from cell lysates. 
However, direct interaction of purified full length CD82 protein with ganglioside has not yet been 
shown. This study demonstrates the interaction of full length CD82 protein with the ganglioside GM2 
by ELISA, and did not require the presence of any other components of the cell membrane. This 
interaction was further explored by surface plasmon resonance and solid state NMR techniques.   
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1. Introduction 
1.1 Tetraspanins 
Tetraspanins are a family of transmembrane proteins found in all eukaryotic cells and are 
characterised by four membrane spanning domains connected by two extracellular loops. 
Although there are many membrane proteins with four transmembrane domains, the tetraspanin 
group is distinguished by several conserved amino acid sequences including the CCG motif in the 
large extracellular loop (1). To date, 33 tetraspanins have been observed in human cells.  Their 
functions range from controlling cell motility to mediating fertilisation, viral infection and immune 
response. Tetraspanins are thought to mediate most of their activities via lateral interactions with 
neighbouring components of the cell membrane. It has been observed that tetraspanins form 
clusters in the cell membrane known as ‘tetraspanin enriched microdomains’ or TERMs. These 
microdomains are highly populated by tetraspanins as well as other membrane proteins such as 
integrins and gangliosides, facilitating intermolecular interactions (1).  
1.1.2 Tetraspanin Enriched microdomains 
Tetraspanin enriched microdomains (fig. 1), are areas of the plasma membrane highly 
populated by tetraspanins. TERMs originally came to light due to their resistance to treatment 
with detergents. Studies revealed TERMs to be rich in several other membrane molecules 
including integrins, receptor tyrosine kinases and G-protein coupled receptors, giving rise to the 
notion that close association of these molecules favours formation of complexes with 
tetraspanins, resulting in signal transduction. There are three types of interaction known to occur 
within TEMs. (i) covalent interactions between tetraspanin and integrins and some tetraspanin-
tetraspanin associations, (ii) non-covalent tetraspanin-tetraspanin interactions and (iii) non-direct 
interactions with cholesterol and gangliosides (1)(2). For the majority of tetraspanins, no ligands 
have been discovered. Hence, interest has been focused on the lateral interactions of 
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tetraspanins and their neighbouring membrane components to elucidate their function. In 
particular, the tetraspanin web and its composition is thought to be a key factor influencing 
tetraspanin activity by bringing molecules into close proximity and thus encouraging cross-talk 
between them. The TERM is highly dynamic, with molecules constantly moving into or out of the 
microdomain and the changes in TERM composition determine tetraspanin activity (3). 
Figure 1. Structure of Tetraspanin Enriched Microdomains (TERM). Tetraspanins form clusters in the plasma 
membrane. TEMs are highly populated by tetraspanins as wells as associated molecule including integrins, gangliosides 
and Ig molecules. TEM composition regulates signalling across the membrane (3).   
 
1.2 CD82 
CD82, also known as TSPAN27 or KAI1, is a tetraspanin initially found to be involved in 
activation of T-cell receptors in lymphocytes. It is highly expressed in prostate, lung and liver 
tissues as well as in leukocytes (4). It was first implicated in cancer by a genetic screen for 
metastasis suppressors in prostate cancer. Orthotopic implantation of lung cancer cells infected 
by adenovirus encoding CD82 in a rat model showed reduced tumour metastasis to the lymph 
nodes (5). Breast cancer cell lines transfected with CD82 show decreased migration and invasion 
while CD82 knock-out cells exhibited increased motility (6). Lack of CD82 is associated with poor 
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prognosis in prostate and breast cancer patients (7). Inhibition of metastasis is critical for the 
development of highly effective cancer therapies as the major cause of death for cancer patients 
is not the growth of the primary tumour but metastasis to other anatomical regions. The role of 
CD82 in tumour metastasis is therefore of considerable interest.  
1.2.1 CD82 Structure 
 
The atomic resolution structure of CD82 has not been determined, but has been 
modelled on the closely related tetraspanin CD81 (fig. 2)(1). CD82, like all members of the 
tetraspanin family, possesses four transmembrane domains linked by small and large extracellular 
loops (SEL and LEL) with short intracellular N and C terminal tails. The LEL comprises a large 
portion of the protein and consists of a constant region which is conserved in other tetraspanins, 
and a variable domain which differs in sequence and structure across the tetraspanin family and 
is thought to give rise to the specific functions of different tetraspanins despite their homology (8).  
The constant domain of the LEL is known to contain 3 α-helices. The variable domain of the LEL 
contains two α-helices (8) and is thought to be involved in interactions with other membrane 
components. It features a conserved CCG motif of which the two cysteine residues form 
Figure 2. Structure of Tetraspanins. Tetraspanins contain four 
transmembrane domains linked by small and large extracellular loops 
(SEL and LEL), with unstructured C and N terminal tails. The LEL 
consists of a constant domain depicted in yellow, and a variable 
domain shown in blue. The constant domain contains three α-helices 
while the variable region contains two α-helices and a highly 
conserved CCG motif. Two disulphide bridges are essential for correct 
LEL folding. Tetraspanins are also palmitoylated at membrane proximal 
cysteine residues (1). 
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disulphide bonds with cysteines in other parts of the loop to fold the protein into its correct 
conformation (9). CD82 is heavily glycosylated, ranging in molecular weight from 28KDa to up to 
60KDa. It is also palmitoylated at intracellular cysteine residues proximal to the plasma 
membrane and this post translational modification is shown essential for correct trafficking of 
CD82 to the membrane (10).  
1.2.2 CD82 Function 
Cholesterol and gangliosides have been shown to interact with CD82. However, no ligand 
has been determined to directly bind to CD82, and the tetraspanin does not possess any 
enzymatic activity (9). Its effects are therefore thought to be mediated by lateral interaction with 
other membrane molecules. The mechanism by which CD82 inhibits metastasis is unclear 
although several possibilities have come to light including interactions with integrins, other 
tetraspanins and receptor tyrosine kinases (fig. 3)(9). 
Figure 3. Anti-metastatic Actions of CD82.  CD82 interacts with integrins which mediate cell adhesion and invasion 
while interaction with the EGF receptor regulates cell motility to inhibit tumour metastasis(9). 
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1.2.3 CD82 Interaction with Integrins 
Integrins are transmembrane proteins which are involved in mediating cell attachment to 
components of the extracellular matrix (ECM) such as laminin and fibronectin (fig. 3). They have a 
major role in regulating cell motility but are also involved in cellular signalling. They have been 
found to localise to tetraspanin webs and are known to interact with tetraspanins (9). CD82 was 
found to co-immunoprecipitate with α4β1 integrin (11). Co-localisation of CD82 and α4β1 was 
also observed by confocal microscopy. Ovarian cancer cells transfected to overexpress CD82 
exhibited increased adhesion via α5β3 integrin and reduced cell motility, suggesting that the anti-
metastatic actions of CD82 may be mediated by interaction with integrins by regulating cell 
adhesion (12). 
1.2.4 CD82 Interaction with Receptor Tyrosine Kinases 
Interaction of CD82 with receptor tyrosine kinases such as c-met and EGFR (epithelial 
growth factor receptor) has been observed. EGFR is a cell surface receptor activated by growth 
factors and activates pathways responsible for cell proliferation, migration and DNA synthesis. 
Dysregulation of EGFR is therefore implicated in cancer.  CD82 associates with EGFR and triggers 
internalisation of the receptor by endocytosis to reduce surface levels of EGFR (13). Reduced 
activation of EGFR resulted in decreased formation of lammelipodia and decreased cell migration, 
providing the basis of a possible mechanism for the anti-metastatic effect of CD82. CD82 co-
immunoprecipitates with protein kinase C, calveolin-1 and the ganglioside GM3, components that 
are commonly found in tetraspanin webs. CD82 associates with EGFR and recruits calveolin-1. 
Calveolin-1 recruits protein kinase C which interacts with EGFR and promotes receptor 
internalisation. This data suggests formation of a complex consisting of EGFR, CD82, GM3, 
calveolin and protein kinase C and reveals the importance of TERMs for mediating tetraspanin 
activity (14).   
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C-met is a receptor tyrosine kinase involved in wound healing. It is frequently upregulated 
in prostate cancer and is associated with increased tumour metastasis and tumour related 
angiogenesis. CD82 is able to inhibit c-met activation in two ways. It can prevent interaction of c-
met with its ligand HGF (hepatocyte growth factor) and it can also disrupt ligand independent 
activation of c-met by integrins. CD82 upregulation also correlates with reduced activation of 
signalling molecules downstream of c-met including FAK (focal adhesion kinase), the tyrosine 
kinase Src, and p130cas. P130cas is of particular interest as it activates the Rac pathway which 
mediates cytoskeletal reorganisation for cell motility. Inhibition of c-met by CD82 is therefore 
another possible mechanism for metastasis suppression (15). However, a direct interaction 
between CD82 and c-met has yet to be demonstrated. It has been suggested that these two 
molecules may not be directly associated, but instead rely on recruitment of adapter proteins 
such as Grb2 to mediate signalling between them (15).  
Several studies have documented that overexpression of CD82 has an inhibitory effect on 
Src. Src is involved in the formation of focal adhesion complexes and is therefore implicated in 
tumour metastasis. CD82 upregulation reduces Src activity and increases cell aggregation while a 
more recent study found that in addition to inhibiting cell motility via Src, CD82 expression 
downregulated VHL and HIF1a downstream of Src, suggesting a possible role for CD82 in 
inhibiting angiogenesis, a process which is associated with metastasis (16).  
In addition to integrin mediated cell adhesion, CD82 may also influence adhesion via E-
cadherin and β-catenin. CD82 upregulation increased E-cadherin mediated cell adhesion. 
Immunoflourescent staining revealed that CD82 expression induced relocalisation of β-catenin to 
E-cadherin adhesion complexes, possibly stabilising the adhesion complex to reduce cell motility 
(17). 
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1.2.5 Other Activities of CD82 
Most research on CD82 has focused on its anti-metastatic role and reduction in cell 
motility. However, metastasis is a complex process encompassing several events including 
breakdown of the extracellular matrix to allow cell migration, evasion of anoikis upon cell 
detachment, invasion of blood vessels and angiogenesis. CD82 has also been implicated in these 
processes. 
CD82 expression impairs synthesis of urokinase plasminogen activator receptor (uPAR), 
an enzyme which breaks down components of the ECM, a process which occurs at early stages of 
metastasis. This prevents cells from disseminating from the primary tumour and inhibits tumour 
invasion of the surrounding tissue (18). A separate study found that CD82 stabilises the 
interaction between uPAR and the integrin α5β1. This association disrupts binding of uPA ligand 
to the receptor, inhibiting activation of proteolysis pathways (19). A screen for genes involved in 
apoptosis highlighted CD82, and further research found that CD82 is associated with increased 
production of reactive oxygen species which trigger apoptosis (20).  
 
1.3 CD82 and Gangliosides 
Gangliosides are part of the glycosphingolipid family of glycoproteins which are present in 
eukaryotic cell membranes. Glycosphingolipids consist of a hydrophilic carbohydrate head group 
which protrudes from the cell membrane and a ceramide tail embedded in the external leaflet of 
the bilayer (fig. 4) (21). Gangliosides, so called due to their abundance in ganglions, possess a 
sialic acid residue attached to the head region. The number of sialic acid residues and their 
position varies between different gangliosides. Gangliosides are over-expressed in a range of 
cancers and have been pursued as a target for tumour immunotherapy (22). Gangliosides are 
involved in various cellular processes including modulation of enzyme activity and cellular 
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signalling. They can interact with selectins to modulate cell adhesion and have also been shown 
to interact with growth factor receptors such as EGFR and with integrins. They are also able to 
form lipid domains within the cell membrane and are often present in the tetraspanin web (23). 
(24) 
 
The interaction of gangliosides with tetraspanins is under investigation. It has been 
observed that levels of gangliosides GM1 and GD1a were significantly increased in HB2 cells 
transfected to over-express CD82 compared to control HB2 cells. Immunofluorescence revealed 
that GD1a co-localised with clusters of CD82 and EGFR on the cell membrane. Other studies have 
noted that GD1a expression has an inhibitory effect on EGFR signalling suggesting that GD1a may 
be involved in regulating the interaction between CD82 and EGFR (25). Inhibition of ganglioside 
synthesis resulted in reduced co-immunoprecipitation of CD82 with known binding partners 
including EGFR, α3 integrin and CD151, supporting the notion that gangliosides are involved in 
stabilising interactions of CD82 (26). Ganglioside depletion resulted in the redistribution of CD82 
from the cell periphery to random clusters over the cell surface suggesting a role for gangliosides 
in organising the distribution of tetraspanins in TEMs. Ganglioside depletion in HB2/CD82 cells 
Figure 4. The Structure of Gangliosides. 
Gangliosides consist of a hydrophilic head group 
and a hydrophobic ceramide tail. The head group 
contains glucose and galactose as well as sialic 
acid residues. The number and position of sialic 
acid residues varies between gangliosides (24). 
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resulted in reduced EGFR phosphorylation while control HB2/Zeo cells showed no change in EGFR 
phosphorylation, suggesting that CD82 is required for gangliosides to modulate EGFR activity.    
The interaction between CD82 and GM2 was demonstrated by using a pull down assay 
from YTS1 bladder cancer cells transfected to express CD82. CD82 was found to bind to GM2 
coated beads while beads coated with GM3 or Gb4 did not show any CD82 binding suggesting 
that CD82 interacts with GM2 directly and specifically. CD82 and GM2 were also observed to 
colocalise by confocal microscopy. Inhibition of ganglioside synthesis resulted in increased 
motility of YTS1/CD82 cells in response to HGF, while YTS1 control cells showed no difference (27). 
A separate study by the same group using silica nanospheres coated with gangliosides revealed 
that nanospheres coated with a complex of GM2 and GM3 had a significantly greater inhibitory 
effect on motility of YTS1 cells than either ganglioside alone. CD82 also bound to a greater extent 
to beads coated with the GM2/GM3 complex suggesting that the GM2/GM3 heterodimer may 
interact with CD82. Cells treated with nanospheres coated with the heterodimer showed reduced 
activation of the cMet pathway which has been implicated in CD82 mediated metastasis 
suppression. This suggests that the GM2/GM3 heterodimer interacts with CD82 and modulates its 
effects on the cMet pathway (28). 
1.4 Aims 
Interaction of full length CD82 protein expressed in mammalian cells with the ganglioside 
GM2 has previously been demonstrated by co-immunoprecipitation using cellular lysates. The 
aim of this study is to determine if a direct interaction between CD82 and GM2 or GD1a occurs 
using purified full length CD82 protein produced in yeast. The CD82-ganglioside interaction will be 
assessed by several techniques including ELISA, surface plasmon resonance and solid state NMR 
in order to better understand the role of the CD82-ganglioside interaction in the inhibition of 
cancer metastasis. 
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2. Materials and Methods 
2.1 Antibodies and Reagents 
The anti-CD82 monoclonal antibody M104 and anti-CD81 M38 antibody were kindly 
provided by Dr O. Yoshie (Shionogi Institute, Osaka, Japan). The anti-CD82 monoclonal 
antibody TS82 was kindly provided by Dr E. Rubinstein (INSERM U268 Villejuif, France). Anti-CD82 
monoclonal antibody ɣC12 was kindly provided by Dr H. Conjeaud (Institute Cochin, Paris, France). 
Anti-CD82 antibody TS82b was purchased from Abcam Plc. Anti-His-HRP conjugated antibody was 
purchased from Invitrogen. Polyclonal goat anti-mouse and polyclonal goat anti-rabbit HRP 
conjugated antibodies purchased from Dako were used as secondary antibodies for Western 
Blotting. Anti-GM2 polyclonal antibody was purchased from Abcam Plc. Additional anti-GM2 
polyclonal antibody was purchased from Calbiochem. Monosialoganglioside GM2 and 
disialoganglioside GD1a were purchased from Matreya LLC Lipids and Biochemicals. 
2.2 Production of Full Length CD82 Protein 
 Full length CD82 protein was expressed in Pichia Pastoris as described in Jamshad et al, 
2008 (29) by R. Sundaresan. The cell pellet was resuspended in 50 mM Tris pH 8.0, 200 mM NaCl, 
0.5 mM EDTA, 2mM TCEP and Complete protease inhibitor (Roche). Cells were lysed by pressure 
cell disruption at 30,000psi. Cell debris was removed by centrifugation at 10,000g for 30 minutes. 
The supernatant was ultracentrifuged at 100,000g for 1.5 hours. The supernatant was removed 
and DPC (dodecylphophocholine) or β-OG (β-octyl glucoside) was added to the protein pellet to a 
final concentration of 2%. The protein was purified by filtration through a nickel sepharose 
column. Three glycosylation sites in the extracellular domain were mutated from Asn to Gly and 
five palmitoylation sites in the membrane proximal region were mutated from Cys to Ala to 
obtain homogenous protein samples.  
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2.3 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS PAGE) and Western 
Blotting 
All gels were run using Biorad Pre-Cast 18 well gels. Samples were loaded with Laemmli 
Buffer containing bromophenol blue and if required, were reduced with 99% β-mercaptoethanol 
(Sigma Aldrich). Gels were stained with Instant Blue Coomassie Stain (Expedeon) or used for 
Western Blotting. SDS PAGE separated proteins were transferred to a nitrocellulose blotting 
membrane (Biotrace, Life Sciences). Membranes were blocked with 5% skimmed milk-PBST for 
one hour, and then probed with the appropriate primary antibody for one hour. Membranes 
were washed 3x20 minutes with PBST and incubated in secondary antibody for one hour. Blots 
were developed using Western Lightning Plus Chemiluminescence Kit (Perkin Elmer Inc.) and 
detected by x-ray film (Amersham Hyperfilm MP, GE Healthcare Ltd.). 
2.4 Immunoprecipitation 
Protein G Sepharose beads (Amersham Biosciences) were washed with 1% Triton PBS 
buffer. Beads were incubated with TS82, TS82b, ɣC12, M104 or M38 antibody overnight on a 
rotary mixer at 4°C. Beads were pelleted and washed. Beads were then incubated with 1 µL of 
CD82 for 1 hour at room temperature on a rotary mixer. Beads were washed with 1% Triton PBS 
buffer, resuspended in Laemmli buffer and heated to 95⁰C for 5 minutes to elute protein. 
Samples were then run on SDS gels. Western blots were carried out using TS82b antibody. 
2.5 ELISA 
Plates were incubated overnight with 10 µM GM2 or GD1a diluted to 10 µM in 9:1 
methanol and water. Plates were washed with PBS 0.001% Tween and blocked with 3% BSA PBST.  
Plates were washed and CD82 diluted in PBS 0.001% Tween was added to the relevant wells and 
incubated for 1 hour. Plates were washed and incubated with TS82 antibody (1:1000 dilution in 
PBS 0.001% Tween) for 1 hour, followed by incubation with mouse secondary antibody (1:10000 
  
 
 
12 
 
  
diluted in 3%BSA).  Presence of GM2 or GD1a was confirmed by incubating wells with GM2 or 
GD1a antibody followed by the relevant secondary antibody. Plates were developed with TMB 
Reagent (Pierce) and absorbance was detected at 630nm with an Elx800 plate reader. 
2.6 SPR 
Sensor chips CM5, L1 and NiNTA were purchased from Biacore, GE Healthcare. HBS buffer, 
PBS buffer, amine coupling kits and nickel coating kits were also purchased from Biacore, GE 
Healthcare. SPR was conducted with a Biacore 3000 instrument. Ligands were immobilised to the 
chip and interaction with the analyte was detected as a change in angle of resonance represented 
as response units. NiNTA chips were prepared for ligand binding using a nickel coating kit as per 
manufacturer’s instructions. Where required, ligands were amine coupled to the L1 or CM5 chips 
using an amine coupling kit as per manufacturer’s instructions. Several SPR approaches were used. 
1. An L1 chip was coated with POPC (Palmitoyl-oleoyl-phosphatidyl-choline) and POPC ganglioside 
liposomes and binding was detected by anti-ganglioside antibody. 2. NiNTA chip was coated with 
CD82 (0.25%DPC) and binding was detected by anti-HIS antibody. 3. CM5 chip was coated with 
anti-HIS antibody to capture CD82 protein. 4. HIS antibody was amine coupled to CM5 chip to 
capture CD82. 5. GM2 was amine coupled to CM5 chip and binding was detected with anti-CD82 
antibody. 6. GM2 was amine coupled to L1 chip. CD82 was passed over the flow cells and binding 
detected by anti-HIS or TS82 antibody. Gangliosides and CD82 were diluted to 10 µM in the 
relevant flow buffer. Antibodies were diluted to 1:500 in the relevant flow buffer. Chips were 
washed with 100 mM NaOH and 40 mM CHAPS. 3% BSA was used as a blocking buffer.  
2.7 Liposome Preparation 
Liposomes were prepared with 0.5 mM POPC and 10 µM ganglioside. Solutions were 
dried to a film with nitrogen gas. 1 ml PBS buffer was added to each sample. Liposomes were 
freeze-thawed 10 times with dry ice and then centrifuged for 1 minute at 1000rpm. Liposomes 
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were then passed through an extruder (Avestin) with a 0.1 µm Nuclepore membrane 20 times. 
Liposomes were collected in an eppendorf and stored at 4C. 
2.8 Sample preparation for NMR 
Preliminary samples were prepared containing POPC (Avanti Polar Lipids Inc.) and POPC 
with GM2. 15mg POPC was added to one glass tube. 15mg POPC and 0.5l 1mM GM2 was added 
to a separate glass tube. Each tube was dried with nitrogen gas and samples were resuspended in 
1ml TRIS buffer (20mM, pH7.5).Samples were vortexed and left at room temperature for 1 hour.  
Samples were ultracentrifuged at 50000rpm for 1 hour at 4 degrees. The supernatant was 
removed. 1 ml TRIS buffer was added to each tube and the pellet resuspended. The samples were 
ultracentrifuged again at 50000rpm for 1 hour at 4 degrees. The supernatant was removed and 
the pellets were stored at 4 degrees prior to measurement at the University of Nottingham for 
solid-state NMR (ssNMR) analysis by Dr Boyan B. Bonev. ssNMR experiments were carried out on 
a Varian 400MHz VNMRS Direct Drive spectrometer equipped with 4 mm T3 MAS NMR probe 
(Varian, Palo Alto CA, USA), as described in Sanghera et al 2011.  
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3. Results 
3.1 Immunoprecipitation 
 
Figure 6. Immunoprecipitation of CD82 solubilised in -OG and DPC. IgG beads were coated with TS82, TS82b, ɣC12 
and M104 for pull down of CD82. Western blots were probed with c16, TS82b and anti-His antibodies. CD82 (-OG) was 
immunoprecipitated by all anti-CD82 antibodies used. CD82 (DPC) was not immunoprecipitated by TS82 but was 
immunoprecipitated by other antibodies. 
 
Immunoprecipitation of CD82 was carried out to determine the binding ability of αCD82 
antibodies prior to use in ELSIA experiments. CD82 solubilised in β-OG (β-octyl glucoside) and DPC 
(dodecylphosphocholine) was successfully pulled down with TS82, TS82b, ɣC12 and M104 
antibodies (fig. 6). Of these, M104 showed the strongest binding to CD82, while ɣC12 was the 
weakest. Each antibody recognises a different epitope on the CD82 protein, suggesting that 
protein in both samples is in the correct conformation. The TS82 antibody did not 
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immunoprecipitate CD82 solubilised in DPC, suggesting that binding of DPC molecules to CD82 
protein may have masked the epitope for TS82. Control lanes were negative although a band was 
detected with the anti-CD81 antibody M38 with both β-OG and DPC solubilised proteins. These 
bands were only observed when blots were probed with TS82b antibody and were positioned 
slightly higher than the other bands for CD82. They may be due to non-specific reactivity of the 
M38 antibody. 
3.2 ELISA Assays 
Initial ELISA assays were carried out to confirm the binding of gangliosides GD1a and GM2 
to the 96 well plate (fig. 7).  GD1a coated wells gave a highly positive result with both antibody 
dilutions suggesting GD1a had bound to the plate. However, the control wells containing no 
ganglioside and wells without primary antibody also gave very high absorbance readings, 
suggesting non-specific binding of the secondary antibody. The GM2 coated wells gave 
absorbance values that were very similar to the un-coated control wells, also suggesting non-
specific antibody activity.  
Figure 7. Titration of anti-ganglioside antibodies. GD1a and GM2 binding to the plate was detected by the relevant 
antibody at dilutions of 1 in 5000 and 1 in 10000 Non-specific antibody binding was detected for both GD1a and GM2. 
Error bars represent standard deviation. 
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The ELISA was repeated with decreasing concentrations of secondary antibody, and also 
with secondary antibody diluted in 3% BSA rather than wash buffer as indicated in the original 
protocol (fig. 8). Decreasing the secondary antibody concentration reduced the non-specific 
binding observed in the ganglioside free wells but also reduced absorbance in the ganglioside 
coated wells. In contrast, wells probed with secondary antibodies diluted in 3% BSA however, 
showed very low non-specific binding in the negative wells. A strong positive result in the GD1a 
coated wells confirmed that GD1a could bind to the plate. With GM2 (fig. 9), a convincing positive 
result was not observed in any of these conditions as the control wells and GM2 coated wells 
gave similar results consistently. The low activity of the anti-GM2 antibody was therefore 
suspected and a different GM2 antibody was ordered (Calbiochem). 
 
Figure 8. Detection of GD1a binding to ELISA plate using various secondary antibody conditions. Secondary antibodies 
diluted to 1 in 10000 in 3% BSA PBST gave the optimum result. 
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Figure 9. Detection of GM2 binding to ELISA plate using various secondary antibody conditions. High non-specific 
binding was observed in each case. 
 Activity of the new GM2 antibody was tested by ELISA (fig. 10). The antibody gave a 
strong positive signal at a dilution of 1:500 with wells coated with 10uM GM2. However, 
uncoated wells also gave an absorbance reading of 0.55 indicating non-specific binding to plates. 
The difference between the absorbance values in the positive and negative wells was statistically 
significant according to the student’s unpaired T-test (p<0.05) and was therefore used in further 
experiments.  
 
Figure 10. Testing of GM2 antibody. The second GM2 antibody detected GM2 bound to the ELISA plate when diluted 
to 1:500. Non-specific binding was observed in uncoated wells but the difference was statistically significant according 
to the student’s T-test, *(p<0.05). 
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A preliminary ELISA incubating ganglioside coated plates with various concentrations of 
CD82 (-OG) was carried out (fig. 11). Binding of CD82 was detected using three different 
antibodies, TS82, M104 and HRP conjugated anti-His antibody. GM2 coated wells incubated with 
50 and 100 µM CD82 gave high absorbance results, 0.6 and 0.8 respectively with TS82, suggesting 
that CD82 is able to bind to GM2. With GD1a, increasing concentrations of CD82 gave increasing 
absorbance results with both TS82 and M104 although the maximum absorbance detected was 
less than 0.4, suggesting that CD82 is less able to bind to GD1a than GM2 or that the GD1a-CD82 
interaction is too weak to be observed by this method. Anti-His HRP conjugated antibody gave 
low absorbance values in each case, which in light of the positive results with both TS82 and 
M104 suggests that this antibody is unable to bind to CD82 in this assay. 
 
Figure 11. Preliminary ELISA with B-Og solubilised full length protein added to ganglioside coated plates. Increased 
absorbance was detected with GM2 coated wells incubated with 50 and 100uM CD82. 
 
The ELISA was repeated with added control wells which were not coated with ganglioside 
but were incubated with CD82 (fig. 12). The wells lacking ganglioside gave absorbance readings 
comparable to wells coated with GD1a, with increasing concentrations of CD82 giving higher 
readings.  These results indicated the non-specific binding of CD82 to the plate and not to GD1a. 
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With GM2, the absorbance readings were still significantly higher than wells containing no 
ganglioside (p<0.05), as determined by the unpaired T-test, indicating that CD82 is able to bind to 
GM2.  
 
Figure 12.  ELISA results of GD1a and GM2 coated plates incubated with 10, 50 and 100µM β-Og solubilised full 
length CD82. GM2 coated wells showed increased absorbance when incubated with CD82. The increase in absorbance 
was statistically significant (p<0.05) despite high readings for ganglioside free wells. GD1a coated wells did not show 
any statistically significant difference from control wells.  *, results of statistical significance according to the student’s 
T-test. 
 
Additional ELISA assays were carried out with the aim of reducing the non-specific binding 
of CD82 to the plate (fig. 13). PBST, 1% BSA in PBST and 3% BSA in PBST were tested in the 
blocking buffers to decrease non-specific binding of CD82, by blocking any open binding sites on 
the plate, prior to addition of CD82.The best result was obtained with 3% BSA for ganglioside free 
wells. However, the absorbance was higher than with GM2 coated wells. GM2 free wells were 
also coated with cholesterol overnight. These wells showed reduced absorbance and therefore 
reduced binding of CD82 compared to GM2 coated wells although absorbance values were still 
high. 
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Figure 13. Optimisation of ELISA using different blocking buffers. PBST, 1% BSA, 3% BSA were tested to reduce non-
specific binding of CD82. Coating the wells with cholesterol was also tested. Absorbance readings were still high in 
ganglioside free wells. 
 
Additional ELISAs were carried out using shingosine and sphingomyelin to coat 
ganglioside free wells. Although CD82 showed reduced binding to these wells compared to GM2 
coated wells, the absorbance was still higher than with uncoated wells (fig. 14).  
As the β-OG solubilised CD82 protein showed high nonspecific binding in several ELISAs, 
assays were next carried out using the DPC solubilised protein (fig. 15). However, absorbance 
results for M104, anti-His antibody and TS82b antibody were all below 0.25, demonstrating that 
DPC solubilised CD82 did not bind to GM2 or bind non-specifically to the plate.  
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Figure 14. Blocking of uncoated wells with sphingosine and sphingomyelin. Sphingosine and sphingomyelin did not 
reduce non-specific binding of CD82 to the plate. 
 
 
Figure 15. ELISA using DPC solubilised full length CD82 protein. Binding of CD82 to GM2 was not detected. 
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In an alternative approach, plates were incubated overnight with β-OG solubilised CD82 
(figs. 16 and 17). Wells were incubated with 20uM GM2 for 1 hour and binding of GM2 was 
detected with GM2 antibody. Binding of CD82 to the plate was confirmed using TS82 antibody. 
Absorbance results were all below 0.3 suggesting that GM2 was unable to bind to CD82 in this 
assay.  
 
Figure 16. Confirmation of binding of β-Og solubilised CD82 to ELISA plate. Binding of CD82 to the plate was detected 
by TS82 antibody (1:1000) 
 
Figure 17. ELISA with wells coated with 50uM β-Og solubilised CD82. Absorbance readings were low for various 
concentrations of anti-GM2 antibody, indicating binding of GM2 was not detected.  
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3.3 Surface Plasmon Resonance 
 An L1 Biacore sensor chip was coated with POPC or POPC-ganglioside liposomes. Coating 
of  the  L1  chip  with  POPC, POPC-GD1a  and POPC-GM2 liposomes was confirmed by  addition of 
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Figure 18. SPR sensograms of L1 Chip coated with POPC, POPC-GD1a and POPC GM2 liposomes. A. Coating of L1 chip 
with liposomes. Green, POPC, Magenta, POPC-GD1a. Cyan, POPC-GM2. Red, uncoated. Increase in relative response 
indicates liposome coating. ↓, addition of liposomes. B. Addition of GD1a antibody to POPC only and POPC-GD1a flow 
cells. Binding of GD1a antibody confirms presence of GD1a on the chip surface (magenta) while POPC only flow cell 
gave no response ↓, addition of GD1a antibody. C. Addition of GM2 antibody to untreated (red) and POPC-GM2 coated 
flow cells. Increase in relative response confirmed presence of GM2 on chip surface. ↓, addition of GM2 antibody.  
 
anti-GD1a and anti-GM2 antibody (fig. 18). However, addition of 0.25% DPC buffer caused a sharp 
decrease in response, indicating removal of the liposomes coating the chip (fig. 19). The sensitivity 
of the liposome coating to detergent prevented addition of detergent solubilised CD82 protein to 
this setup. 
Figure 19. Addition of 0.25% DPC to the POPC, POPC-GD1a and POPC GM2 liposome coated L1 chip. ↓, addition of 
0.25% DPC caused uncoating of the liposomes. Green, POPC, Magenta, POPC-GD1a. Cyan, POPC-GM2. Red, uncoated. 
 
In an alternative approach, CD82 in 0.5% DPC was immobilised on a NiNTA sensor chip by 
binding of the 6xHis-tag to Ni2+ on the sensor chip surface (fig. 20). However, binding of CD82 was 
also detected in the non-nickel coated flow cell indicating non-specific protein binding. Addition 
of ts82b antibody gave an increase in response units for the nickel coated flow cell, but not for 
the non-coated flow cell, indicating binding of CD82, although the response was very low.  
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Figure 20. SPR sensograms for NiNTA chip coated with CD82. A. Coating of sensor chip surface with CD82.  Magenta, 
nickel coated flow cell. Red, uncoated flow cell. ↓, increase in response units for the uncoated flow cell upon addition 
of CD82 (0.5% DPC) demonstrates non-specific interaction of CD82 with sensor chip surface. B. ↓, addition of TS82b 
antibody. Magenta, nickel coated flow cell loaded with CD82. Green, nickel coated flow cell without CD82. A small 
response to TS82b is observed in the CD82 coated flow cell.  
 The experiment was repeated using CD82 solubilised in 0.5% β-OG to reduce non-specific 
binding. Once again, CD82 interacted with both nickel coated and uncoated flow cells, indicating 
non-specific binding (fig. 21). Binding of CD82 to ganglioside could not be assayed by this method 
since proper controls could not be achieved.  
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Figure 21. SPR sensogram of addition of CD82 (0.5%). DPC to NiNTA chip. Magenta, nickel coated flow cell. Red, 
uncoated flow cell. CD82 loading gave identical responses for both nickel coated and uncoated flow cells indicating 
non-specific binding.  ↓, addition of CD82, 0.5% DPC. 
 
3.4 Solid State NMR 
 Solid state NMR (ssNMR) is advantageous for studying membrane proteins as it 
does not require the protein to be soluble. Therefore, ssNMR was used to observe the interaction 
between CD82 and GM2. Preliminary preparations of POPC and POPC with GM2 were analysed by 
ssNMR to check that GM2 could be observed in the samples. The spectra for POPC and POPC with 
GM2 were almost identical, indicating that the peaks observed were for POPC and GM2 was not 
detected (fig. 22).  Alternative methods of sample preparation for ssNMR analysis are being 
trialled. 
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Figure 22. SsNMR spectra of POPC and POPC-GM2 micelles. A. POPC micelles. B. POPC-GM2 micelles. Spectra for both 
POPC and POPC-GM2 were identical, indicating that GM2 was could not be detected. 
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4. Discussion 
 Transmembrane proteins are notoriously difficult to purify using recombinant methods 
and protein yield is often very low. As a result, research into this field has lagged behind others. 
As transmembrane proteins are embedded in the lipid bilayer and are hydrophobic, they are 
poorly soluble in aqueous conditions and can become unstable, losing their conformation and 
functionality (30). Transmembrane proteins may be solubilised in detergent. However, this can 
affect protein function and interfere with certain biological assays and prove problematic for 
structure determination using x-ray crystallography or NMR.  These issues were also encountered 
in in this study. Although β-OG and DPC were used to solubilise the CD82 by masking the 
hydrophobic transmembrane regions of CD82, they also bound to the hydrophobic surface of the 
ELISA plate. Despite this, the interaction between CD82 and GM2 was still observed by ELISA. 
Attempts to confirm this interaction by surface plasmon resonance were unsuccessful while 
efforts to observe the CD82-GM2 interaction by ssNMR are on-going. This data also suggests that 
full length CD82 protein expressed in yeast has similar activity to CD82 expressed in mammalian 
systems.  
 These results support research by Odintsova et al and Todeschini et al showing that CD82 
binds to gangliosides, in particular GM2, and this interaction is important for CD82 function (25, 
26). It is known that CD82 in the presence of GM2 inhibits phosphorylation of tyrosine residues in 
C-Met to inhibit cell proliferation and motility in response to HGF binding to the cMet receptor 
and also inhibits HGF independent cMet signalling via interaction with integrins. In cancer cells, 
CD82 is downregulated, so that inhibition of cMET is relieved, promoting  metastasis (27). It is 
unclear why GM2, with its apparently anti-metastatic activity, is elevated in cancer. It has been 
observed that GM2 is upregulated in melanoma and increases tumour growth and metastasis (31). 
This contrasts with the anti-metastatic effects observed on cMet in complex with CD82. Elevation 
of gangliosides in tumour cells may be as a result of cells gaining a cancer phenotype or may be 
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part of a compensatory or negative feedback mechanism in an attempt to regain control of cell 
motility. This is a point for further research. It is possible that low levels of GM2 facilitate anti-
metastatic activities of CD82, while upregulation of GM2 could alter TEM composition and 
compartmentalisation of other membrane components to modify cell behaviour to a metastatic 
phenotype. Alteration of TEM composition may favour different combinations of molecular 
interactions and result in activation of different signalling pathways. It has been demonstrated 
that depletion of GD1a alters CD82 distribution on the cell surface (26). It may be interesting to 
observe if depletion of GM2 has a similar effect on CD82 and would indicate the role of GM2 in 
CD82 compartmentalisation. 
 Ganglioside GM2 has previously been highlighted as a possible target for cancer 
therapeutics and there have been several attempts to use anti-GM2 antibodies to disrupt GM2 
activity. A study by Hanibuchi et al 1998 using chimeric anti-GM2 antibodies showed promising 
results in vivo by inducing antibody dependant cytotoxicity and reducing tumour metastasis (32). 
However, the use of chimeric antibodies is limited due to the risk of adverse effects. More 
recently, Yamada et al 2011 have produced a humanised anti-GM2 antibody which reduced 
metastasis and triggered apoptosis in a mouse model of small cell lung carcinoma (33). Two of the 
monoclonal anti-GM2 antibodies used in this study, BIW 8962 and KM8927 are currently in 
clinical trials for the treatment of melanoma. With these promising prospects, an intriguing 
aspect is the role of CD82 in this situation. It is possible that the anti-metastatic effects of these 
antibodies may be related to the interaction of GM2 with CD82. This raises CD82 as a possible 
target for cancer therapeutics, and a better understanding of this interaction may lead to the 
production of more specific anti-GM2 antibodies inhibiting the pro-metastatic activities of GM2 
while conserving the anti-metastatic interaction with CD82.  
 While using the full length CD82 protein posed problems with the use of aqueous 
solutions and maintaining protein stability, it may be possible to observe the interaction with 
  
 
 
30 
 
  
GM2 by using the extracellular domain of the tetraspanin. Tetraspanin extracellular domains, 
specifically the large extracellular loop, have been demonstrated to be functionally active by 
several studies including Monk et al 2002 who observed that the ECD of CD82 and several other 
tetraspanins could inhibit infection of macrophages by HIV (human immunodeficiency virus) (34). 
An alternative approach to overcome the problems posed by detergents would be to use 
nanodiscs, originally developed by Sligar et al(35). Nanodiscs consist of phospholipids held 
together into a bilayer by membrane scaffold protein which shields the hydrophobic region of the 
bilayer from aqueous solution. Membrane proteins solubilised in detergent can be embedded 
into the nanodisc and the detergent subsequently removed. This maintains protein stability and 
also has the advantage of mimicking the structure of the plasma membrane allowing proteins to 
be studied in an environment that more closely resembles their natural state. These nanodiscs 
can be bound to NiNTA sensor chips and used in SPR for binding studies. 
 The interaction between CD82 and GM2 has important implications on our understanding 
of the role of CD82 in cancer metastasis. This study demonstrated the CD82-GM2 interaction by 
ELISA while SPR and ssNMR approaches require refinement in order to confirm this observation. 
The functional significance of this interaction must also be explored. In particular, the apparently 
contrasting role of GM2 and CD82 in metastasis needs further investigation. Although anti-GM2 
antibodies are in development, a greater understanding of the role of GM2 and its interaction 
with CD82 could lead to the design of a more effective anti-metastatic treatment. 
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